Profound Medical

This is a Page excerpt. It will be displayed for search results

Profound Medical achieves a **78% gross margin** in Q3 2026 while reducing cash used in operating activities by **56% sequentially**. The company expands its U.S. distribution network and prepares leadership for its next growth phase.

Nov 2026Profound Medical Corp.News article

Profound Medical partners with Cook Medical’s iMRI Division to distribute **TULSA-PRO®** through the **Copernicus™ program**, broadening its U.S. sales network. The agreement integrates the device into Cook Medical’s **iMRI Suite**, aiming to enhance commercial reach and sustain recurring revenue growth for Profound. Both companies leverage their expertise to strengthen market positioning in integrated MRI-guided therapy solutions.

Oct 2026Profound Medical Corp.News article

Profound Medical and Telix Pharmaceuticals collaborate to educate physicians and prostate cancer centers on integrating Telix’s PSMA-PET imaging with Profound’s MRI-guided TULSA-PRO treatment. The partnership aims to advance prostate cancer care by combining diagnostic imaging and targeted therapy technologies. Both companies will jointly promote PSMA-informed treatment approaches in clinical settings.

Oct 2026Profound Medical Corp.News article

Profound Medical Corp. names **Richard Fabian** as its new **President**, effective immediately. Fabian replaces Mathieu Burtnyk, PhD, who transitions to the role of **Chief Technology Officer**. The company specializes in **interventional MRI (iMRI) procedures** and operates as a commercial-stage medical device developer.

Sep 2026Profound Medical Corp.News article